Micronucleus-inducing and antitumor activity of three newly synthesized bridged nitrogen atom-containing pyrimidines.
OBJECTIVE
To study micronucleus (MN)-inducing and antitumor activity of 3 newly synthesized compounds having condensed nitrogen-containing heterocyclic structures with a bridged nitrogen atom (code numbers - DGB-216, DGS-618 and DGS-623).


METHODS
The compounds were tested for MN-inducing activity in SH-SY5Y and HeLa tumor cell lines at doses close to IC50 (assessed by means of trypan blue dye exclusion technique ) and 1/2 of IC50 after 24 h incubation without recovery time. In parallel, apoptotic cells were also registered after 24 h incubation of cells with the compounds, staining with Hoechst 33258 and investigation under fluorescent microscope. The compounds were also studied in albino mice bone marrow cells at doses of 1/2, 1/5 and 1/10 of LD50 injected intraperitoneally (i.p.) twice at 0 and 24 h and preparing bone marrow smears 24 h after the last injection. The antitumor activity of the compounds was studied on mouse Ehrlich ascites carcinoma assay by measuring the mean survival time.


RESULTS
Only DGS-618 showed cytotoxity at concentrations close to 75.0-80.0 microg/ml; the others were not cytoxic at concentration about 250.0 microg/ml. No one substance induced significant number of cells with MN and apoptosis compared with the negative control. Only DGS-618 was slightly mutagenic in MN-assay at dose of 1/2 of LD50. In contrast, this compound was absolutely inactive in Ehrlich tumor assay. Only DGS-623 was active and induced significant increase in the mean lifespan of mice by 31.0-24.0% in 2 experiments.


CONCLUSIONS
The compound DGS-618 which does not induce MN both in vivo and in vitro and shows antitumor activity in vivo is worth testing in other tumor models. Recent publications show that the search of antitumor agents among pyrazolyl-pyrimidine-containing compounds could be successful because some of them synthesized in the USA and Japan possess expressed antitumor activity.
Nersesyan
A
A
National Center of Oncology, Yerevan, Armenia. armenn@freenet.am
Muradyan
R
R
Arsenyan
F
F
Danagulyan
G
G
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects*; D045744:Cell Line, Tumor / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006367:HeLa Cells; D006801:Humans; D008297:Male; D051379:Mice; D048629:Micronuclei, Chromosome-Defective / Q000139:chemically induced*; D015162:Micronucleus Tests; D011743:Pyrimidines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D011743:Pyrimidines